Lyra Therapeutics, Inc.
LYRA
$0.73
-$0.01-1.22%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -72.00% | -86.34% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -72.00% | -86.34% | |||
| Cost of Revenue | -421.89% | -20.80% | |||
| Gross Profit | 424.07% | 18.37% | |||
| SG&A Expenses | 13.60% | -36.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.11% | -27.04% | |||
| Operating Income | -10.43% | 25.75% | |||
| Income Before Tax | -16.18% | 19.56% | |||
| Income Tax Expenses | -33.33% | 50.00% | |||
| Earnings from Continuing Operations | -16.16% | 19.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.16% | 19.54% | |||
| EBIT | -10.43% | 25.75% | |||
| EBITDA | -10.68% | 25.86% | |||
| EPS Basic | -15.54% | 38.62% | |||
| Normalized Basic EPS | -11.72% | 42.89% | |||
| EPS Diluted | -15.54% | 38.62% | |||
| Normalized Diluted EPS | -11.72% | 42.89% | |||
| Average Basic Shares Outstanding | 0.54% | 31.08% | |||
| Average Diluted Shares Outstanding | 0.54% | 31.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||